Formulation Development
Codexis & Nestlé Health Science Sign Development Agreement
Codexis, Inc. and Nestlé Health Science have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical….
Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates
Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. recently announced a collaboration to develop mazindol (MZD) CR product candidates for the treatment of….
Mereo BioPharma & Oncologie Enter Global Licensing Agreement
Mereo BioPharma Group plc and Oncologie, Inc. recently announced a global license agreement for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently…
CytoDyn Files for Breakthrough Therapy Designation With the FDA
CytoDyn Inc. recently announced it has filed for Breakthrough Therapy designation (BTD) with the US FDA for the use of leronlimab as an adjuvant therapy…
Adaptimmune Announces SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Adaptimmune Therapeutics plc recently announced two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. There…
Novavax Granted Fast-Track Designation
Novavax, Inc. recently announced the US FDA has granted Fast-Track Designation for NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M, in adults…
AUTOINJECTOR PLATFORM - Identifying New, Enhanced Device Delivery Solutions for Chronic Diseases
Karima Yadi, MSc, and Lionel Maritan, MSc, believe identifying enhanced needle solutions and offering integrated system solutions to serve the chronic disease market is a great step toward addressing improved patient outcomes and adherence.
PERSONALIZED MEDICINE - Personalizing Cancer Immunotherapy: Trends in Biomarker Discovery
Emile Youssef, MD, PhD, says due to tumor heterogeneity, the plasticity and diversity of cancer cells, and a multitude of other factors, biomarker development is a challenge, and thus explores four trends in cancer biomarker discovery.
DEVELOPMENT TIMELINES - Drug Development Times, What it Takes - Part 1
Josef Bossart, PhD, explains how accurately estimating a product’s clinical development timelines is more than simply adding up the individual timelines, almost always optimistic. You need to “know” the numbers, not just calculate them.
BIOPROCESSING - A New Era: Why the Time Has Come for Biopharma to Move to Continuous Bioprocessing
Dr. Martin Smith explains why the pharma industry must embrace continuous processing if it’s to survive and thrive in an era of global personalized medicine.
EXECUTIVE INTERVIEW - Foamix Pharmaceuticals: Delivering Pharmaceuticals to the Skin Through a Foam
David Domzalski, Chief Executive Officer of Foamix, discusses his company’s innovative approach to drug delivery using foam to treat dermatological conditions, like acne and rosacea.
OLIGONUCLEOTIDE DELIVERY - Dectin-1 Receptor-Mediated Delivery of Oligonucleotide Drugs Complexed With Schizophyllan Dendritic Cells & Macrophages
Kenji Arima, PhD, and Akihiko Watanabe, PhD, introduce NapaJen Pharma’s technology with a specific focus on solving some of the current challenges of oligonucleotide therapeutics.
MARKET BRIEF - Tumor-Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
Cheryl L. Barton, PhD, and Bianca Piachaud-Moustakis, PhD, believe the role of TIL therapy as an anticancer therapy in melanoma and possibly other solid tumors holds great promise and could become a viable course of treatment in the future.
Nurix Therapeutics & Sanofi Establish Strategic Collaboration
Nurix Therapeutics, Inc. recently announced a global strategic collaboration with Sanofi to discover, develop, and commercialize a pipeline of innovative targeted protein….
Sebia Enters Development Agreement With Sanofi
Sebia recently announced it is entering into an agreement with Sanofi to develop an in vitro diagnostic (IVD) test that mitigates the potential interference caused by……
WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
WPD Pharmaceuticals recently announced Wake Forest University received a patent from the United States Patent and Trademark Office (USPTO) for patent 105019210 (issued under application…
Oxford BioTherapeutics Initiates Dose-Escalation Portion of Phase I Clinical Trial
Oxford BioTherapeutics Ltd. recently announced the initiation of the dose-escalation portion of its US Phase 1 program for OBT076, a CD205 targeting antibody-drug conjugate (ADC),…
Zai Lab & Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial
Zai Lab Limited and Novocure recently announced the first patient has been enrolled in a Phase 2 pilot clinical trial evaluating the safety and efficacy…
TYME Announces First Patient Dosed in Pivotal Trial
Tyme Technologies, Inc. recently announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval…
Bayer Exercises Right to Enter Follow-On Research & Collaboration Option Agreement
Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, recently announced the companies will continue the development of two crop protection programs.…
